Dr. Ranjana Advani is a Professor of Medicine at Stanford University specializing in the field of lymphoma. She holds an endowed chair (Saul Rosenberg Professor) and oversees all aspects of treatment of the vast majority of adult lymphoma patients. Her primary research interests include improving care for non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) patients by optimizing front line regimens, developing novel agents and targeted therapy for refractory and recurrent disease, advancing correlative studies involving biomarkers, and addressing long-term outcomes. She leads multi-institutional efforts as a national study Principal Investigator (PI) or Co-PI on several targeted therapies, translational and imaging studies and has published extensively in the peer reviewed literature. She is a member of the lymphoma core committee for the Eastern Cooperative Oncology Group and the NCCN guidelines committee for Non-Hodgkin Lymphoma and Hodgkin Lymphoma (vice chair), member of ODAC (Oncology Drug Advisory Committee) to the FDA, and has completed a term serving as the co-chair of the National Cancer Institute Lymphoma Steering Committee.